USFDA1 Dec 2025, 11:40 am
Wockhardt's New Drug Application for Breakthrough Antibiotic Zaynich Accepted by US FDA
AI Summary
Wockhardt Ltd. announced that the United States Food and Drug Administration (US FDA) has formally accepted the New Drug Application (NDA) for its novel, first-in-class antibiotic Zaynich. This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the US FDA. Zaynich has been granted Fast Track designation by the US FDA, recognizing its potential to address urgent and unmet medical needs. The antibiotic has garnered international attention for its potent activity against highly resistant Gram-negative pathogens.
Key Highlights
- US FDA accepts Wockhardt's New Drug Application for Zaynich, a first-ever NDA acceptance for an Indian Pharmaceutical Company.
- Zaynich is a novel, first-in-class antibiotic with a new B-lactam enhancer mechanism.
- Zaynich has demonstrated life-saving impact through compassionate use in critically ill patients in both India and the United States.
- Zaynich has been granted Fast Track designation by the US FDA, recognizing its potential to address urgent and unmet medical needs.
- Zaynich has garnered international attention for its potent activity against highly resistant Gram-negative pathogens.